

Figure. S2 Validation Of the Tumor Size Cutoffs among (A) All T1N0M0 Breast Cancer Patients, (B) HR+/HER2- T1N0M0 Breast Cancer Patients, (C) HR+/HER2+ T1N0M0 Breast Cancer Patients, (D) HR-/HER2+ T1N0M0 Breast Cancer Patients, (E) HR-/HER2- T1N0M0 Breast Cancer Patients, and (F) HER2+ T1N0M0 Breast Cancer Patients.

